Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.
This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$CYCA: Cytta Corp and FIZUAS Team Up to Enhance Drone and Streaming Tech for Law Enforcement: Cytta Corp. (Stock Symbol: CYCA)
June 25, 2024
Click here:
https://www.einpresswire.com/article/722643501/cytta-corp-and-fizuas-team-up-to-enhance-drone-and-streaming-tech-for-law-enforcement-cytta-corp-stock-symbol-cyca
From the article:
Technology Solutions Provider Addressing Various Industries for Integration, Streaming, Transfer and Storage of Video and Audio Data.
Partnered with FIZUAS Unmanned Aircraft Systems to Dominate the American Drone Reseller and Advanced Streaming Technology Market.
Launched Crisis Alert and Response Emergency System Mobile Application to Revolutionize School Safety.
Instant SOS Alert Automatically Triggers a Video Call That is Shared with All Emergency Responders Responsible for Protecting a School.
Initiative for Florida Law Enforcement Agencies Generates Overwhelming Response Amid New Drone Regulation Changes.
Strong Success for Groundbreaking AI-Enhanced Marketing Campaign in Florida.
Multiple Florida Police Departments and Sheriff's Offices Choosing CYCA CyttaCOMMS as their Drone Streaming Solution.
$OCTO and $MMMW great recent news with $MMMW with a very low market cap and huge potential with new solar cost cutting technology.
$OCTO News July 01, 2024
NASDAQ Grants Eightco’s Request for Continued Listing on The Nasdaq Capital Market
https://finance.yahoo.com/news/nasdaq-grants-eightco-request-continued-123000894.html
$IFUS and $MMMW new developments
$IFUS - Research representatives from SUARC will collect samples of SGP+™ and sugarcane bagasse from IFUS' Napoleonville, LA Operations on Thursday May 16, 2024.
https://finance.yahoo.com/news/impact-fusion-international-inc-announces-131500044.html
$FAVO EF Hutton news and $MMMW news today on 105 percent increase in power output.
$IFUS - IFUS had discovered how to naturally breakdown lignin, this would be in fact the "Holy Grail" of energy and nutrition for beef and dairy cattle.
https://finance.yahoo.com/news/impact-fusion-international-inc-louisiana-131500558.html
$FAVO - EF Hutton, with its extensive experience and proven track record in investment banking, will provide investment banking services to FAVO Capital, Inc.
https://finance.yahoo.com/news/favo-capital-engages-investment-bank-114500969.html
$BIEI Attorney Letter with Respect to Current Information
https://www.otcmarkets.com/otcapi/company/financial-report/407064/content
Recent developments $MMMW and $FAVO. New product news with $MMMW
$FAVO - The decision to engage Turner Stone underscores FAVO Capital's commitment to maintaining the highest standards of financial integrity and transparency. FAVO Capital aims to enhance its financial reporting processes and ensure continued PCAOB compliance within the industry.
https://finance.yahoo.com/news/favo-capital-inc-appoints-turner-171500774.html
$HNRC May 15th News Story Houston Natural Resources reports Q1 results
https://seekingalpha.com/news/4106860-houston-natural-resources-reports-q1-results?utm_source=otcmarkets&utm_medium=referral&feed_item_type=news
$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market
Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership
LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.
A Strategic Move in Response to Growing Demand
This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.
Quote from Mike Elliott, VP of Business Development
"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."
Expanding CyttaAIR's Reach
This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.
About Cytta Corp:
Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.
The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.
About FIZUAS Unmanned Aircraft Systems
FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.
Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662
Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com
Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com
Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708
SOURCE: Cytta Corp.
$FAVO News June 11, 2024
FAVO Capital, Inc. Appoints Turner, Stone & Company, LLP as Auditors
https://finance.yahoo.com/news/favo-capital-inc-appoints-turner-171500774.html
$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
$AGBA News April 30, 2024
Building a Digital Economy Titan: AGBA and Triller Combine in $4 Billion Merger
https://finance.yahoo.com/news/building-digital-economy-titan-agba-130000244.html
$FAVO - Global Finance's eleventh annual Innovators Awards program celebrates entities across various categories, including banks, companies, and fintechs, that consistently pioneer new paths and develop innovative financial tools.
https://finance.yahoo.com/news/favo-capital-stewards-investment-capital-130500781.html
$CBDW 1606 Corp. was able to connect with a multitude of independent sales organizations ("ISO's") and public companies and are in productive talks to bring them the new "IR Chat" technology. https://finance.yahoo.com/news/1606-corp-recaps-massive-response-120000119.html
$AURI U.S. Drug Control Agency Moves to Reclassify Marijuana in a Historic Shift That Would Benefit Auri Inc. and Knockout Gummies Brand
https://www.newmediawire.com/news/u-s-drug-control-agency-moves-to-reclassify-marijuana-in-a-historic-shift-that-would-benefit-auri-inc-and-knockout-gummies-brand-7074637
$TKMO SO UNDER VALUED STOCK
By end of December 2023
ASSETS: $3,914,178
REVENUES: $2,691,950
$AVRW: Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$PDGO - Phase I Operation, Inc. has signed a Letter of Intent to utilize the Company to acquire 100% interest in 12 producing oil and gas wells, inclusive of the land where the wells are located, in an all stock transaction. The oil and gas wells are located in Oklahoma.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-And-Gas-Inc-Announces-Change-in-Control-and-Letter-of-Intent?id=425854
$HNRC HNRC CEO Frank Kristan Shares Insights on 2023 Financials, 2024 Outlook, Digital Asset ‘Gold’ Token, and Sponsored SPEC NYSE: HNRA on ‘The Street Reports Podcast’ – Tune In!
https://thestreetreports.com/hnrc-ceo-frank-kristan-shares-insights-on-2023-financials-2024-outlook-digital-asset-gold-token-and-sponsored-spec-nyse-hnra-on-the-street-reports-podcast-tune-in/
$WRIT - WRIT CEO Eric Mitchell stated, We look forward to helping promote this event and supporting our veterans. We anticipate great things to come from this collaboration as we focus on the May 18, 2024, event and future events.
https://www.otcmarkets.com/stock/WRIT/news/WRIT-Media-Group-Inc-Announces-Digital-Marketing-and-Merchandising-Agreement-with-Patriots-Fest-Music-Festival-Set-for-M?id=438516
$CBDL - The last few months have seen our team transforming everything about our approach to CBD and reimagining our branding and online presence.
https://finance.yahoo.com/news/cbd-life-sciences-provides-exciting-120000086.html
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.
C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.
D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.
Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.
"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.
About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)
Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.
Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL90042&sd=2024-04-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
SOURCE NRx Pharmaceuticals, Inc.
$VGLS ON WATCH -- HUGE UPDATE COMING SOON...
$VGLS
— DACE (@DACE0325) April 18, 2024
The natural resources sector remains a cornerstone of the stock market, fueling growth and driving investor interest. From renewable energy to mining, it’s a dynamic landscape where innovation meets opportunity. 🌍💼 #NaturalResources #StockMarket #Investing
The future looks bright for $VGLS! 💼 With a strategic focus on real estate investment, we're poised to seize new opportunities and drive growth.
🚀 The future looks bright for $VGLS! 💼 With a strategic focus on real estate investment, we're poised to seize new opportunities and drive growth. Stay tuned as we embark on this exciting journey towards a prosperous future! 🌟🏢 #VGLS #RealEstate #Growth
— DACE (@DACE0325) April 18, 2024
Trending $ABQQ $FSRN…
$AGBA - The challenges faced in 2023 prompted successful changes to AGBA's business model, resulting in increased focus and efficiency. The implementation of significant cost-cutting measures is expected to reduce normalized operating expenses to a level for strong growth and profitability.
https://www.marketwatch.com/press-release/agba-group-is-positioned-for-hong-kong-s-rebounding-macro-environment-with-business-refinements-and-growth-strategies-f566e8f4
$IQST is heating up, and word is, $1 is within reach when they announce their latest acquisition.
https://www.prnewswire.com/news-releases/iqst--iqstel-q1-record-breaking-revenue-exceeds-50m-not-including-recent-acquisition-302114251.html
$GTVH Lavish Entertainment, Inc. Expands Presence in Event Production Industry Through the Acquisition of ABI Create
https://www.globenewswire.com/news-release/2024/04/11/2861416/0/en/Lavish-Entertainment-Inc-Expands-Presence-in-Event-Production-Industry-Through-the-Acquisition-of-ABI-Create.html
$PDGO - In connection with the previously announced change in control, the new management of PDGO has commenced the process of identifying and initiating targeted acquisitions for PDGO.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241
$NXGB - In its first quarter of operations under the NxGen Brands ownership, Mad House is set to achieve topline revenues of somewhere between $200,000 and $250,000 in first quarter sales.
https://finance.yahoo.com/news/nxgen-brands-inc-releases-bullish-123000349.html
$TREIF Treatment AI Passes Medical School Clinical Exam with 92% Success Rate https://finance.yahoo.com/news/treatment-ai-passes-medical-school-123000812.html
$TREIF Treatment AI Passes Medical School Clinical Exam with 92% Success Rate https://finance.yahoo.com/news/treatment-ai-passes-medical-school-123000812.html
OTC: $TREIF CSE $TRUE NEWS
Treatment.com AI Funded by the National Institute of Health to Develop a Culturally Sensitive AI Approach to Health Equity
$EDXC's low price is chance for us, ain't gonna miss that.
$TWOH is hopeful for a market rebound from its recent downturn and aims to deliver robust returns to investors starting as soon as the overhanging shares from the previous finance partner are exhausted. https://twohandsgroup.com/blog/twoh-weathering-the-storm
$TWOH is hopeful for a market rebound from its recent downturn and aims to deliver robust returns to investors starting as soon as the overhanging shares from the previous finance partner are exhausted. https://twohandsgroup.com/blog/twoh-weathering-the-storm
$IFBC A Ground-Floor Opportunity in a Growing Energy Drink Company #IFBC https://reddit.com/r/PennyStocksWatch/comments/1bk9scq/ifbc_a_groundfloor_opportunity_in_a_growing/
One compelling reason to consider investing in $TWOH is the definitive potential for more strategic acquisitions of small wholesale grocery distributors. https://twohandsgroup.com/blog/twoh-weathering-the-storm
$EDXC - Endexx Corporation Embarks on Strategic Transformation: Leadership Evolution and Intensified Focus on HYLA's Market Dominance
https://finance.yahoo.com/news/endexx-corporation-embarks-strategic-transformation-030020439.html
$EVKRF - To complete the Technical Report, the Company used the results of prior soil samples, geophysical surveys, and drilling on the property, to help identify structure and target areas favorable to lithium accumulation and determine next steps for its overall exploration plan.
$DTMXF - Power Hour buying opportunity.
Branding
Use AnalyticsGPT to discern the values and messages that truly resonate with your audience. A strong, data-driven brand narrative ensures you remain top-of-mind, fostering customer loyalty and repeat business.
https://www.datametrex.com/analyticsgpt
$ARTM News March 05, 2024
American Nortel Communications, Inc. Announces the Availability of its IOS Platform for NewborhoodTalks.com
https://finance.yahoo.com/news/american-nortel-communications-inc-announces-133000601.html
$CYIO - The company is especially excited to be partnering with a tier-1 US carbon offset project that has recently launched as an independently validated and verified project on the American Carbon Registry (ACR).
https://finance.yahoo.com/news/cyios-corp-shareholder-carboncred-carbon-150000460.html
$EDXC recently experienced a downturn due to a missed filing deadline. However, the exciting part is that once they resolve their paperwork issues, there's significant potential for a substantial upward surge. 🌕 This might just be the rebound opportunity we've all been anticipating, so it's crucial to stay alert. Conduct thorough due diligence, but my intuition suggests that this could be a golden chance for gains. 📈💰 Don't overlook this – it's shaping up to be a promising investment prospect! 🚀
https://finance.yahoo.com/news/endexx-corporation-announces-transition-auditor-140000342.html
Followers
|
625
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
38207
|
Created
|
05/31/10
|
Type
|
Free
|
Moderator stockseekerok | |||
Assistants TPX |
OTC MARKET PLAYS
Here We Will Follow The Hot Stocks Of The Day
Any Stock That is Moving Positively Will be A hot Stock Of The Day
Here we Dedicate to Low Float Stocks Becuase when they Move they provide the Largest Gains
We Strive To Locate any Stock That is Moving intraday.
We like to see a level 2 setup that shows that the Intraday Play has potential to provide a large move
Join Us And Play The Hot Stocks Of The Day
Investors Just do Not Realize That When A stock Is at its Lowest Share Structure Is when the Most Money Can Be Made.
Yes The Lack Of Volume and Trading History Concerns you.
Why Is there a lack Of Volume ?
Because Investors will not get together and see that If Many buy the stock and create the momentum that the rest of IHUB will join Right In.
A Stock that is not Promoted and Has a Low Share Structure will Rise with Volume.
If you Want to Make Money Then Sign Up For The Alerts In The Sticky Posts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |